Patents by Inventor Gunnar Kvalheim
Gunnar Kvalheim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230192804Abstract: The present invention provides a nucleic acid molecule encoding a specific binding molecule capable of binding an h TERT peptide comprising the amino acid sequence set forth in SEQ ID NO: 1 when the peptide is presented by a Class II Major Histocompatibility Complex (MHC), wherein the specific binding molecule comprises a first polypeptide comprising a variable region of an ?-chain and a second polypeptide comprising a variable region of a ?-chain of a T-cell receptor (TCR), and wherein: (a) the variable region of an ?-chain comprises CDR sequences CDR1, CDR2 and CDR3 which respectively comprise the amino acid sequences set forth in SEQ ID NOs: 2, 3 and 4; and (b) the variable region of a ?-chain comprises CDR sequences CDR1, CDR2 and CDR3 which respectively comprise the sequences set forth in SEQ ID NOs: 5, 6 and 7. Recombinant constructs, vectors and host cells comprising such nucleic acid molecules are also provided, as are specific binding molecules encoded by such nucleic acid molecules.Type: ApplicationFiled: February 27, 2019Publication date: June 22, 2023Inventors: Gustav GAUDERNACK, Gunnar KVALHEIM, Else Marit INDERBERG, Sébastien WÄLCHLI
-
Publication number: 20220177573Abstract: The present disclosure relates to compositions comprising compounds or cells able to specifically bind immunoglobulin kappa (IgKappa) and membrane molecule CD 19 under physiological conditions. In particular, the disclosure relates to a combinatorial chimeric antigen receptor (cCAR) with antigen binding domains specific for the antigen CD19 and the immunoglobulin (Ig) Kappa light chain and their expression in immune effector cells to target cells expressing CD19 and IgKappa, and such immune cells for use in treating B-cell cancers.Type: ApplicationFiled: July 8, 2019Publication date: June 9, 2022Inventors: Gunnar Kvalheim, Erlend Smeland, Else Marit Inderberg, Sébastien Wälchli, Harald Holte, June Helen Myklebust, Steinar Funderud, Hakan Köksal
-
Publication number: 20220127574Abstract: The present invention relates to a modified natural killer (NK) cell and its use in personalised medicine. The modified NK cells of the present invention are non-immunogenic, meaning that they are able to be administered to any recipient subject without being rejected by the host immune system (they are “universal”). In a first embodiment the non-immunogenic NK cells are modified to express CD3 to allow a T-cell Receptor (TcR) to be expressed. In a further embodiment the non-immunogenic NK cells are further modified to express a TcR together with the CD3 co-receptor. Co-expression of CD3 with a specific TcR results in the modified NK cells showing antigen-specific cytotoxicity towards target cells. Universal NK cells can thus be targeted against specific antigens, and may thus be used in personalised medicine, particularly in the field of oncology.Type: ApplicationFiled: September 23, 2021Publication date: April 28, 2022Inventors: Sébastien Wälchli, Else Marit Inderberg Suso, Gustav Gaudernack, Gunnar Kvalheim
-
Patent number: 11155786Abstract: The present invention relates to a modified natural killer (NK) cell and its use in personalised medicine. The modified NK cells of the present invention are non-immunogenic, meaning that they are able to be administered to any recipient subject without being rejected by the host immune system (they are “universal”). In a first embodiment the non-immunogenic NK cells are modified to express CD3 to allow a T-cell Receptor (TcR) to be expressed. In a further embodiment the non-immunogenic NK cells are further modified to express a TcR together with the CD3 co-receptor. Co-expression of CD3 with a specific TcR results in the modified NK cells showing antigen-specific cytotoxicity towards target cells. Universal NK cells can thus be targeted against specific antigens, and may thus be used in personalised medicine, particularly in the field of oncology.Type: GrantFiled: January 22, 2016Date of Patent: October 26, 2021Assignee: Oslo Universitetssykehus HFInventors: Sébastien Wälchli, Else Marit Inderberg Suso, Gustav Gaudernack, Gunnar Kvalheim
-
Publication number: 20210115401Abstract: Methods are disclosed for the generation of immunosuppressive regulatory T cells. The methods can include contacting a population of CD4+CD25? T cells with a T cell receptor (TCR)/CD3 activator, a TCR co-stimulator activator, and rapamycin. Kits for the generation of immunosuppressive regulatory T cells, methods of use, and cell populations are also disclosed.Type: ApplicationFiled: October 5, 2020Publication date: April 22, 2021Inventors: Tanja AARVAK, Anne-Marie RASMUSSEN, Gunnar KVALHEIM, Walter Gabriell Borelli PIEDRAS, Anne BRUNSVIG
-
Publication number: 20200009238Abstract: The present invention relates to peptides presented on the cell surface of cells in the MHC class I (MHC I) context in which the invariant chain has been engineered to favor loading of specific antigens and generate CD8+ T-cell activationType: ApplicationFiled: September 25, 2019Publication date: January 9, 2020Inventors: Sebastien P. WÄLCHLI, Tone Fredsvik GREGERS, Else Marit Suso INDERBERG, Gustav GAUDERNACK, Gunnar KVALHEIM, Oddmund BAKKE
-
Publication number: 20190358263Abstract: The present invention relates to cancer immunotherapy. In particular, provided herein are compositions and methods for improving the efficacy of cell therapies cancer and other diseases.Type: ApplicationFiled: December 7, 2017Publication date: November 28, 2019Inventors: Sebastien Walchli, Else Marit Inderberg, Gunnar Kvalheim, Gustav Gaudernack, Nadia Mensali
-
Publication number: 20190336529Abstract: The present invention relates to TCR molecules which recognise neopeptides produced as a result of the cancer-associated “?1A” frameshift mutation in human TGF?RII. The TCR molecules are capable of binding a peptide of SEQ ID NO: 1 when said peptide is presented by a Class I MHC, and comprise an ?-chain domain and a ?-chain domain, each chain domain comprising three CDR sequences, wherein a) CDRs 1, 2 and 3 of the ?-chain domain have the sequences of SEQ ID NOs: 2, 3 and 4 respectively; and b) CDRs 1, 2 and 3 of the ?-chain domain have the sequences of SEQ ID NOs: 5, 6 and 7 respectively, and wherein one or more of said CDR sequences may optionally be modified by substitution, addition or deletion of 1 or 2 amino acids. Nucleic acid molecules encoding such TCRs are provided, as are soluble TCR molecules with these CDR sequences.Type: ApplicationFiled: May 9, 2017Publication date: November 7, 2019Applicant: Oslo Universitetssykehus HFInventors: Else Marit Inderberg, Gustav Gaudernack, Sèbastien Wälchli, Gunnar Kvalheim
-
Publication number: 20190071640Abstract: Methods are disclosed for the generation of immunosuppressive regulatory T cells. The methods can include contacting a population of CD4+CD25? T cells with a T cell receptor (TCR)/CD3 activator, a TCR co-stimulator activator, and rapamycin. Kits for the generation of immunosuppressive regulatory T cells, methods of use, and cell populations are also disclosed.Type: ApplicationFiled: August 7, 2018Publication date: March 7, 2019Inventors: Tanja AARVAK, Anne-Marie RASMUSSEN, Gunnar KVALHEIM, Walter Gabriell Borelli PIEDRAS, Anne BRUNSVIG
-
Publication number: 20190048061Abstract: The present invention relates to nucleic acid molecules encoding chimeric antigen receptors (CARs) against the antigen CD37. The CARs disclosed herein have complementarity-determining regions (CDRs) derived from the potent monoclonal anti-CD37 antibody HH1, and may be used in immunotherapy to target cells expressing CD37. Such immunotherapy has a particular use in the treatment of B-cell cancers. The CARs of the present invention are highly functional in the redirection of immune cells to kill CD37+ cells, and include humanised CARs of particular use in medical therapy. The present invention also includes vectors comprising the above-described nucleic acid molecules, immune effector cells expressing the aforementioned CARs and the use of such immune effector cells in therapy, particularly adoptive transfer therapy, for cancer, including B-cell malignancies.Type: ApplicationFiled: January 6, 2017Publication date: February 14, 2019Inventors: Erlend SMELAND, Sebastien WALCHLI, Gunnar KVALHEIM, Harald HOLTE, June Helen MYKLEBUST, Steinar FUNDERUD, Else Marit INDERBERG
-
Publication number: 20180010097Abstract: The present invention relates to a modified natural killer (NK) cell and its use in personalised medicine. The modified NK cells of the present invention are non-immunogenic, meaning that they are able to be administered to any recipient subject without being rejected by the host immune system (they are “universal”). In a first embodiment the non-immunogenic NK cells are modified to express CD3 to allow a T-cell Receptor (TcR) to be expressed. In a further embodiment the non-immunogenic NK cells are further modified to express a TcR together with the CD3 co-receptor. Co-expression of CD3 with a specific TcR results in the modified NK cells showing antigen-specific cytotoxicity towards target cells. Universal NK cells can thus be targeted against specific antigens, and may thus be used in personalised medicine, particularly in the field of oncology.Type: ApplicationFiled: January 22, 2016Publication date: January 11, 2018Inventors: Sébastien WÄLCHLI, Else Marit Inderberg SUSO, Gustav GAUDERNACK, Gunnar KVALHEIM
-
Publication number: 20170106066Abstract: The present invention relates to peptides presented on the cell surface of cells in the MHC class I (MHC I) context in which the invariant chain has been engineered to favor loading of specific antigens and generate CD8+ T-cell activationType: ApplicationFiled: June 10, 2015Publication date: April 20, 2017Applicant: UNIVERSITETET I OSLOInventors: Sebastien P. WÄLCHLI, Tone Fredsvik GREGERS, Else Marit Suso INDERBERG, Gustav GAUDERNACK, Gunnar KVALHEIM, Oddmund BAKKE
-
Publication number: 20160024470Abstract: Methods are disclosed for the generation of immunosuppressive regulatory T cells. The methods can include contacting a population of CD4+CD25? T cells with a T cell receptor (TCR)/CD3 activator, a TCR co-stimulator activator, and rapamycin. Kits for the generation of immunosuppressive regulatory T cells, methods of use, and cell populations are also disclosed.Type: ApplicationFiled: July 22, 2015Publication date: January 28, 2016Inventors: Tanja AARVAK, Anne-Marie RASMUSSEN, Gunnar KVALHEIM, Walter Gabriell Borelli PIEDRAS, Anne BRUNSVIG
-
Patent number: 9119807Abstract: Methods are disclosed for the generation of immunosuppressive regulatory T cells. The methods can include contacting a population of CD4+CD25? T cells with a T cell receptor (TCR)/CD3 activator, a TCR co-stimulator activator, and rapamycin. Kits for the generation of immunosuppressive regulatory T cells, methods of use, and cell populations are also disclosed.Type: GrantFiled: November 29, 2012Date of Patent: September 1, 2015Assignee: Life Technologies ASInventors: Tanja Aarvak, Anne-Marie Rasmussen, Gunnar Kvalheim, Walter Gabriell Borelli Piedras, Anne Brunsvig
-
Publication number: 20100129340Abstract: Methods are disclosed for the generation of immunosuppressive regulatory T cells. The methods can include contacting a population of CD4+CD25? T cells with a T cell receptor (TCR)/CD3 activator, a TCR co-stimulator activator, and rapamycin. Kits for the generation of immunosuppressive regulatory T cells, methods of use, and cell populations are also disclosed.Type: ApplicationFiled: October 22, 2009Publication date: May 27, 2010Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Anne-Marie RASMUSSEN, Tanja Arvak, Gunnar Kvalheim, Walter Gabriell Borelli Piedras, Anne Brunsvig
-
Publication number: 20100068193Abstract: Methods are disclosed for the generation of immunosuppressive regulatory T cells. The methods can include contacting a population of CD4+CD25? T cells with a T cell receptor (TCR)/CD3 activator, a TCR co-stimulator activator, and rapamycin. Kits for the generation of immunosuppressive regulatory T cells, methods of use, and cell populations are also disclosed.Type: ApplicationFiled: February 15, 2007Publication date: March 18, 2010Applicant: INVITROGEN DYNAL ASInventors: Anne Brunsvig, Anne-Marie Rasmussen, Borelli Piedras, Gunnar Kvalheim, Tanja Aarvak
-
Patent number: 6893881Abstract: The invention relates to a method for detecting specific target-cells in a simple and time saving way, using paramagnetic particles, antibodies recognizing the Fc portions of target-cell associating antibodies and target-cell associating antibodies directed to specific antigen determinants in the target-cell membranes. Incubation of the cell suspension with a mild detergent and/or second set of antibodies or antibody fragments, prelabeled or not with fluorescent agents, metallocolloids, radioisotopes, biotincomplexes or certain enzymes allowing visualization, with dramatically increase the specificity of the method. The method can further be used for isolation of the target-cells by magnetic field application and kit for performing the method according to the invention is described.Type: GrantFiled: September 10, 1993Date of Patent: May 17, 2005Assignee: Abbott Laboratories, Inc.Inventors: Øystein Fodstad, Gunnar Kvalheim
-
Patent number: 6184043Abstract: The invention relates to a method for detecting specific target-cells in a simple and time saving way, using paramagnetic particles, antibodies recognizing the Fc portions of target-cell associating antibodies and target-cell associating antibodies directed to specific antigen determinants in the target-cell membranes. Incubation of the cell suspension with a mild detergent and/or second set of antibodies or antibody fragments, prelabeled or not with fluorescent agents, metallocolloids, radioisotopes, biotincomplexes or certain enzymes allowing visualization, with dramatically increase the specificity of the method. The method can further be used for isolation of the target-cells by magnetic field application and kit for performing the method according to the invention is described.Type: GrantFiled: June 24, 1997Date of Patent: February 6, 2001Inventors: Øystein Fodstad, Gunnar Kvalheim
-
Patent number: 4910148Abstract: A method and device are provided for separating magnetized particles from biological fluids. Cells such as cancer cells coated with magnetized particles can be separated from uncoated healthy cells. A fluid mixture of cancer cells, healthy cells and magnetizable particles is introduced into a container such as a disposable blood bag which is attached in a cassette on an underlying plane magnetic plane that provides a magnetic field. Incubation is carried out during which the cancer cells become coated with the magnetizable particles. The magnetic field pulls the coated cells down towards the bottom of the bag and anchors them, and uncoated healthy cells are removed from the bag. The separated uncoated healthy cells may be advanced through a final separation unit where any loose magnetizable particles are removed. There is provided means for adjusting vertical distance between the cassette and the magnetic plane and for agitating fluid within the container attached to the cassette.Type: GrantFiled: December 10, 1987Date of Patent: March 20, 1990Assignee: Dynal A. S.Inventors: Otto Sorensen, Gunnar Kvalheim, Eivind Siem
-
Patent number: RE43979Abstract: The invention relates to a method for detecting specific target-cells in a simple and time saving way, using paramagnetic particles, antibodies recognizing the Fc portions of target-cell associating antibodies and target-cell associating antibodies directed to specific antigen determinants in the target-cell membranes. Incubation of the cell suspension with a mild detergent and/or second set of antibodies or antibody fragments, prelabeled or not with fluorescent agents, metallocolloids, radioisotopes, biotincomplexes or certain enzymes allowing visualization, with dramatically increase the specificity of the method. The method can further be used for isolation of the target-cells by magnetic field application and kit for performing the method according to the invention is described.Type: GrantFiled: February 5, 2003Date of Patent: February 5, 2013Assignee: Abbott LaboratoriesInventors: Oystein Fodstad, Gunnar Kvalheim